MaRS Innovation, a Centre of Excellence for Commercialization and Research, today says it is forming a strategic partnership with Pfizer to advance early-stage technologies related to human health in therapeutics and diagnostics.
The partnership's goal is to identify investment opportunities emerging from well-validated scientific research discoveries within MaRS Innovation's 16 member institutions, including the University of Toronto and its nine affiliated teaching hospitals.
To read the original article: Partnership to bridge research and commercialization
